{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:05:05Z","timestamp":1790679905456,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Cystic fibrosis (CF) lung disease progresses by a combination of airway inflammation, bacterial colonization, and infection. Airway inflammation is predominantly neutrophilic and complicates airway clearance therapies through cellular debris; excessive DNA; excessive and viscous mucus; and high concentrations of neutrophils, IL-8, and related cytokines liberated along the nuclear factor-\u03baB signaling pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We conducted a preliminary, single-site, randomized, double-blind, placebo-controlled study to evaluate the effects over 28 days of two dose levels (0.05 mg and 0.1 mg daily) of an older cardiac glycoside, digitoxin, as compared with placebo, on safety, pharmacokinetics, and inflammatory markers in induced sputum obtained from 24 subjects with mild to moderate CF lung disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with CF 18\u201345 years old with any genotype combination were eligible. The primary objective was to measure the effects of digitoxin on IL-8 and neutrophil counts in induced sputum. Secondary objectives were to measure (1) the pharmacokinetics of digitoxin in sera of patients with stable CF; (2) safety indices, including ECG changes and sputum microbiology; (3) the effect of digitoxin on gene expression in nasal epithelial cells of patients with stable CF; and (4) quality-of-life scores using the Cystic Fibrosis Questionnaire\u2013Revised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>It took several weeks to achieve a therapeutic serum level of digitoxin in subjects with CF. No safety concerns emerged during the study. Digitoxin treatment showed a trend toward reduction in sputum free neutrophil elastase and neutrophil counts, but not a reduction in sputum IL-8. Digitoxin treatment did not reach statistical significance for the primary or secondary outcome measures over the 28-day study period. However, the nasal mRNA from the group receiving 0.1 mg of digitoxin daily had a distinct distribution of global gene expression levels as compared with either the 0.05-mg dose or placebo treatment. The mRNAs encoding chemokine\/cytokine or cell surface receptors in immune cells were decreased in nasal epithelial cells at the higher dose, leading to pathway-mediated reductions in IL-8, IL-6, lung epithelial inflammation, neutrophil recruitment, and mucus hypersecretion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At a dose of 0.1 mg daily for 28 days, digitoxin was safe for adults with CF lung disease, but it did not achieve a significant decrease in sputum inflammatory markers.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT00782288).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.201608-649oc","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T17:24:47Z","timestamp":1657646687000},"page":"220-229","source":"Crossref","is-referenced-by-count":23,"title":["Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2719-1834","authenticated-orcid":false,"given":"Pamela L.","family":"Zeitlin","sequence":"first","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Diener-West","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Callahan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seakwoo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"C. Conover","family":"Talbot","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette","family":"Pollard","sequence":"additional","affiliation":[{"name":"Silver Pharmaceuticals, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-1630","authenticated-orcid":false,"given":"Michael P.","family":"Boyle","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9088-8749","authenticated-orcid":false,"given":"Noah","family":"Lechtzin","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"key":"2026020402583747800_bib1","first-page":"CD000407","article-title":"Oral steroids for long-term use in cystic fibrosis","volume":"6","author":"Cheng","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026020402583747800_bib2","first-page":"CD001505","article-title":"Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis","volume":"6","author":"Lands","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026020402583747800_bib3","first-page":"409","article-title":"Inflammatory mediators in CF patients","volume":"70","author":"Hilliard","year":"2002","journal-title":"Methods Mol Med"},{"key":"2026020402583747800_bib4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/infdis\/175.3.638","article-title":"Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis","volume":"175","author":"Noah","year":"1997","journal-title":"J Infect Dis"},{"key":"2026020402583747800_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1165\/ajrcmb.23.2.4214","article-title":"Inflammation and infection in naive human cystic fibrosis airway grafts","volume":"23","author":"Tirouvanziam","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026020402583747800_bib6","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1073\/pnas.0402030101","article-title":"Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells","volume":"101","author":"Srivastava","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020402583747800_bib7","doi-asserted-by":"crossref","first-page":"9631","DOI":"10.1073\/pnas.0504097102","article-title":"Cardiac glycosides inhibit TNF-alpha\/NF-\u03baB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor","volume":"102","author":"Yang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020402583747800_bib8","first-page":"293","article-title":"Preliminary safety profile of digitoxin to treat CF","volume":"49","author":"Callahan","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"2026020402583747800_bib9","first-page":"268","article-title":"Phase II study of digitoxin for CF","volume":"50","author":"Zeitlin","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"2026020402583747800_bib10","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1164\/rccm.200306-731OC","article-title":"Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis","volume":"168","author":"Ordo\u00f1ez","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020402583747800_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/bioinformatics\/19.2.185","article-title":"A comparison of normalization methods for high density oligonucleotide array data based on variance and bias","volume":"19","author":"Bolstad","year":"2003","journal-title":"Bioinformatics"},{"key":"2026020402583747800_bib12","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1093\/nar\/gng015","article-title":"Summaries of Affymetrix GeneChip probe level data","volume":"31","author":"Irizarry","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2026020402583747800_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026020402583747800_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00007611-200093020-00009","article-title":"Comparing the toxicity of digoxin and digitoxin in a geriatric population: should an old drug be rediscovered?","volume":"93","author":"Roever","year":"2000","journal-title":"South Med J"},{"key":"2026020402583747800_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0022-3476(95)70343-8","article-title":"A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis","volume":"126","author":"Eigen","year":"1995","journal-title":"J Pediatr"},{"key":"2026020402583747800_bib16","first-page":"CD000407","article-title":"Oral steroids for long-term use in cystic fibrosis","volume":"12","author":"Cheng","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026020402583747800_bib17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1398-9995.2009.02009.x","article-title":"Genes regulating molecular and cellular functions in noninfectious nonallergic rhinitis","volume":"64","author":"Cardell","year":"2009","journal-title":"Allergy"},{"key":"2026020402583747800_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaci.2004.10.032","article-title":"Altered gene expression profiles in nasal respiratory epithelium reflect stable versus acute childhood asthma","volume":"115","author":"Guajardo","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"2026020402583747800_bib19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/MLG.0b013e31816b4b6f","article-title":"Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma","volume":"118","author":"Stankovic","year":"2008","journal-title":"Laryngoscope"},{"key":"2026020402583747800_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-1-4","article-title":"Digitoxin and its analogs as novel cancer therapeutics","volume":"1","author":"Elbaz","year":"2012","journal-title":"Exp Hematol Oncol"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/14\/2\/220\/66714390\/annalsats_14_2_220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/14\/2\/220\/66714390\/annalsats_14_2_220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:58:45Z","timestamp":1770191925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/14\/2\/220\/8453535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,1]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201608-649oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2]]},"published":{"date-parts":[[2017,2,1]]}}}